UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
1. URGN's Jelmyto shows nearly four years of response duration in a study. 2. OPTIMA II phase 2b study of UGN-102 shows 24.2 months response duration. 3. UGN-102 NDA submitted; FDA PDUFA date set for June 13, 2025. 4. Safety data for UGN-301 indicates promise in bladder cancer treatments. 5. URGN stock rose 7.65% following positive news.